GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Akanda AKAN · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.81

-3.61%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

$836,664

FY2019FY2024

Net income

−$4.1m

FY2019FY2024

Free cash flow

−$6.1m

FY2019FY2024

Shareholders' equity

$4.3m

FY2019FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019
Revenue$836,664$2.2m$2.6m$41,431$2,062—
Operating income−$4.4m−$10.1m−$20.2m−$2.6m−$1.7m−$901,235
Net income−$4.1m−$32.3m−$11.7m−$8.1m−$2.3m−$1.9m
Diluted earnings per share-140.76-1,434.45-19,429.46-0.28-127.10-104.33

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019
Total assets$7.9m$8.8m$39.0m$8.0m$4.3m—
Cash and short-term investments$3.8m$82,816$492,485$3.5m$13,504—
Total liabilities$3.6m$12.7m$12.1m$10.2m$9.3m—
Debt$352,814$4.0m$3.9m$9.6m$9.1m—
Shareholders' equity$4.3m−$3.8m$26.9m−$2.2m−$5.0m—
Shares outstanding0m0m0m29m0m0m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−$4.0m−$1.5m−$11.5m−$6.6m−$1.4m−$642,328
Capital spending−$2.1m−$1,502−$310,946−$576,472−$439,137−$685,922
Free cash flow−$6.1m−$1.5m−$11.8m−$7.1m−$1.8m−$1.3m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-53.8%162.7%—
Operating income-37.3%24.5%—
Net income57.6%81.8%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-855.5%-674.0%-740.6%—
Net margin-4544.5%-1594.7%-1759.3%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings-0.1-0.8-1.1-0.3
Price to sales17.63.916.81.3

Share price return

Finished calendar years

2025202420232022
Return-83%-94%-70%-98%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 5-to-1 reverse split · 13 Apr 2026
  • 5-to-1 reverse split · 12 Jan 2026
  • 3-to-1 reverse split · 26 Aug 2025
  • 2-to-1 reverse split · 14 Nov 2024
  • 40-to-1 reverse split · 23 May 2024
  • 10-to-1 reverse split · 9 Mar 2023

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.